http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011147390-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016 |
| filingDate | 2010-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011147390-A |
| titleOfInvention | NEW APPLICATION |
| abstract | 1. An agent for the prevention or treatment of an inflammatory disease, which is a galactooligosaccharide having a polymerization degree of 3 or more. The tool according to claim 1, where the galactooligosaccharide is selected from the group consisting of Gal (β 1-6) -Gal (β l-4) -Glu, Gal (β l-3) -Gal (β l-4) -Glu trisaccharides , Gal tetrasaccharide Gal (β l-6) -Gal (β 1-6) -Gal (β l-4) -Glu and pentasaccharide Gal (β l-6) -Gal (β l-6) -Gal (β l- 6) Gal (β l-4) -Glu. 3. The tool according to claim 1 or 2 for the prevention or treatment of inflammatory bowel disease. 4. The tool according to claim 1 for the prevention or treatment of colitis, necrotic enterocolitis, pseudomembranous colitis, ulcerative colitis, Crohn’s disease, diverticulitis, ischemia or inflammatory bowel disease. The tool according to claim 1 in the form of a powder, syrup or in the form of a soft lozenge. The agent according to claim 5, wherein 1-10 g of galactooligosaccharide, preferably 2-5 g of galactooligosaccharide, most preferably 2.75 g of galactooligosaccharide are used daily to treat an inflammatory disease. The agent according to claim 5, wherein 1-10 g of galactooligosaccharide, preferably 2-5 g of galactooligosaccharide, most preferably 2.75 g of galactooligosaccharide are used daily for the prevention of inflammatory disease. The use of galactooligosaccharide having a polymerization degree of 3 or more, for the prevention or treatment of inflammatory disease. 9. The use of claim 8, wherein the galactooligosaccharide is selected from the group consisting of Gal (β 1-6) -Gal (β l-4) -Glu, Gal (β l-3) -Gal (β l-4) -Gl trisaccharides , Gal tetrasaccharide Gal (β l-6) -Gal (β 1-6) -Gal (β l-4) -Glu and pentasaccharide Gal (β l-6) -Gal (β l-6) -Gal (β l- 6) Gal (β l-4) -Glu. 10. A method for the treatment and / or prophylaxis of an inflammatory disease, including oral administration of a milk |
| priorityDate | 2009-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419562764 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25206501 |
Total number of triples: 16.